Sana Biotechnology, Inc. Stock Price, News & Analysis

Sana Biotechnology, Inc. (NASDAQ: SANA) will present a business overview at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 4:00 p.m. PT. CEO Steve Harr will lead the presentation, highlighting the company's innovative focus on engineered cell therapies. Interested parties can access the live webcast on Sana's Investor Relations webpage, with a replay available for 30 days post-conference. Sana aims to transform how diseases are treated by creating advanced cell-based medicines, operating in multiple locations including Seattle and Cambridge.

CAMBRIDGE, Mass. -- Flagship Pioneering and Tessera Therapeutics announced Dr. Michael Severino has been appointed as the new CEO of Tessera. With over 20 years of experience in biopharmaceuticals, Severino previously served as Vice Chairman and President of AbbVie, overseeing the development of numerous FDA-approved therapies. Tessera, known for its innovative GENE WRITING technology, aims to transform genetic medicine. Severino's appointment follows Geoff von Maltzahn’s transition to Board Chair, marking a strategic leadership shift as the company prepares for the next phase of growth with its GENE WRITING platforms.

Sana Biotechnology (NASDAQ: SANA) announced a lease agreement for a new 80,000 sq. ft. manufacturing facility in Bothell, WA, expected to save over $100M in the next three years. This facility will replace the Fremont, CA location and is designed to support multiple product candidates as they approach late-stage clinical development. The company also strengthened its leadership team with the appointments of Snehal Patel as Head of Manufacturing and Julie Lepin as Head of Regulatory Affairs. The move aims to enhance internal manufacturing capabilities without affecting program timelines.

Flagship Pioneering has introduced ProFound Therapeutics, leveraging its ProFoundry™ Platform to discover tens of thousands of novel human proteins, significantly broadening therapeutic targets. The company, founded in 2020, aims to transform human health through unprecedented insights into protein interactions. A commitment of $75 million will be utilized for ongoing development and to establish an extensive R&D pipeline, positioning ProFound as a key player in biomedicine's future with vast potential for innovative therapies.

Sana Biotechnology (NASDAQ: SANA) announced that Terry Fry, M.D., Senior VP and Head of T Cell Therapeutics, will serve as Executive Director at the University of Colorado Gates Institute. Dr. Fry, a leader in CAR T therapies, will maintain his role at Sana while collaborating with academia. The Gates Institute, a $200 million initiative over five years, aims at translating lab findings into cell and gene therapies. The collaboration is expected to enhance Sana's scientific endeavors, reflecting the company's commitment to innovative treatments in gene and cell therapy.

Sana Biotechnology (NASDAQ: SANA) reported its Q1 2022 results, revealing a cash position of $657.4 million as of March 31, down from $746.9 million at the end of 2021. Notable research and development expenses surged to $72.7 million, influenced by increased personnel and manufacturing costs. The net loss narrowed to $31.4 million, or $0.17 per share, compared to $180.6 million in Q1 2021. The company plans to file INDs for its ex vivo and in vivo CAR T programs this year. Additionally, strong conference presentations are scheduled for 2022, highlighting ongoing advancements.

Cellarity has appointed Dr. Sandra Horning to its Board of Directors. Dr. Horning, former Chief Medical Officer at Roche, has extensive experience in drug development, having led the approval of 15 new medicines. Her role is expected to strengthen Cellarity's mission of transforming drug creation through innovative approaches that address complex diseases. The company's unique methodologies utilize high-resolution data and machine learning to enhance drug discovery. This strategic move is viewed positively for future product development.

Sana Biotechnology, Inc. (NASDAQ: SANA) announced that it will webcast its presentation at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 3:20 p.m. PT. The presentation will include a business overview by Steve Harr, President and CEO. Investors can access the live webcast on Sana's Investor Relations page, with a replay available for 30 days post-event. Sana focuses on engineered cells as medicines, aiming to repair genes and replace damaged cells, with operations in multiple U.S. locations.

Sana Biotechnology, Inc. (NASDAQ: SANA) announced the acceptance of five abstracts for presentation at the ASGCT 25th Annual Meeting in Washington, D.C. from May 16-19, 2022. The abstracts include two oral presentations on their hypoimmune platform, which aims to enable allogeneic cell transplants without the need for immunosuppression, and two poster presentations on their fusogen platform for targeted gene delivery. The company plans to file two Investigational New Drug applications within the year, focusing on translating their scientific advancements into viable therapeutics.